This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Investors: Mark Your Calendars, Redux

Successful biotech investors keep a close eye on the calendar. Regulatory decisions and clinical trial results move this sector, so it's important to stay on top of these events whenever possible.

To help readers, I've put together another list of biotech catalyst events for the remainder of this year and the beginning of 2005. This calendar builds upon a similar list I put together in September. Judging by the large volume of email I received after that column was published, a biotech calendar is something a lot of people find extremely valuable.

In the interest of brevity, I've kept descriptions here to a minimum, but I'll likely cover many of these events in more detail in the future.

FDA Approval Decision Dates:

  • Biogen Idec (BIIB - Get Report) and Elan (ELN): Antegren, multiple sclerosis, Nov. 25;
  • SuperGen (SUPG): Orathecin, pancreatic cancer, Nov. 26;
  • United Therapeutics (UTHR - Get Report): Remodulin (intravenous formulation), pulmonary arterial hypertension, Nov. 30;
  • Sepracor (SEPR): Estorra, insomnia, Dec. 15;
  • Eyetech Pharmaceuticals (EYET) and Pfizer (PFE - Get Report): Macugen, age-related macular degeneration, Dec. 17;
  • Genzyme (GENZ) and Bioenvision (BIVN), Clofarabine, acute pediatric leukemia, Dec. 30;
  • OSI Pharmaceuticals (OSIP) and Genentech (DNA): Tarceva, non-small-cell lung cancer, Jan. 30, 2005. (OSI has said it expects approval decision to come earlier than Jan. 30, but the company is not any more specific.);
  • American Pharmaceutical Partners (APPX): Abraxane, breast cancer, Jan. 8, 2005;
  • Cyberonics (CYBX): VNS Therapy System, depression, Jan. 31, 2005;
  • Discovery Labs (DSCO): Surfaxin, respiratory distress syndrome (pediatrics), Feb. 13, 2005;
  • Amylin Pharmaceuticals (AMLN): Symlin, diabetes, March 20, 2005. Exenatide, diabetes, April 30, 2005;
  • Adolor (ADLR): Entereg, post-operative ileus, April 25, 2005.
  • Clinical Data:

  • Celgene (CELG - Get Report): Revlimid, myelodysplastic syndrome phase II, Dec. 4-7, 2004;
  • Atherogenics (AGIX): AGI-1067, atherosclerosis, end of 2004;
  • Pharmos (PARS): Dexanabinol, traumatic brain injury phase III, end of 2004;
  • Aphton (APHT): Insegia, gastrointestinal cancer phase III, end of 2004;
  • Isis Pharmaceuticals (ISIS - Get Report): Alifacorsen, Crohn's disease phase III, ulcerative colitis phase II, end of 2004;
  • Corgentech (CGTK): E2F Decoy, peripheral bypass graft failure phase III, late fourth quarter 2004; E2F Decoy, coronary artery bypass graft failure phase III, early 2005;
  • Cell Therapeutics (CTIC): Xyotax, nonsmall cell lung cancer phase III, first quarter 2005;
  • Axonyx (AXYX): Phenserine, Alzheimer's disease, phase II, first quarter 2005;
  • Encysive Pharmaceuticals (ENCY): Thelin, pulmonary arterial hypertension phase III, February 2005;
  • Onyx Pharmaceuticals (ONXX): BAY 43-9006, renal cancer phase III interim analysis, first half 2005.
  • Adam Feuerstein writes regularly for RealMoney.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. He invites you to send your feedback to adam.feuerstein@thestreet.com.

    Check Out Our Best Services for Investors

    Action Alerts PLUS

    Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

    Product Features:
    • $2.5+ million portfolio
    • Large-cap and dividend focus
    • Intraday trade alerts from Cramer
    Quant Ratings

    Access the tool that DOMINATES the Russell 2000 and the S&P 500.

    Product Features:
    • Buy, hold, or sell recommendations for over 4,300 stocks
    • Unlimited research reports on your favorite stocks
    • A custom stock screener
    Stocks Under $10

    David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

    Product Features:
    • Model portfolio
    • Stocks trading below $10
    • Intraday trade alerts
    14-Days Free
    Only $9.95
    14-Days Free
    To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
    Submit an article to us!
    SYM TRADE IT LAST %CHG
    ONXX $0.00 0.00%
    ELN $0.00 0.00%
    BIIB $401.71 0.00%
    CELG $118.71 0.00%
    ISIS $66.37 0.00%

    Markets

    DOW 18,080.14 +21.45 0.12%
    S&P 500 2,117.69 +4.76 0.23%
    NASDAQ 5,092.0850 +36.0220 0.71%

    Partners Compare Online Brokers

    Free Reports

    Top Rated Stocks Top Rated Funds Top Rated ETFs